These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1119 related items for PubMed ID: 18514980

  • 1. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.
    Vaccine; 2008 Jul 04; 26(29-30):3640-6. PubMed ID: 18514980
    [Abstract] [Full Text] [Related]

  • 2. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
    de Vries JJ, Bungener L, Ter Veer W, van Alphen L, van der Ley P, Wilschut J, Huckriede A.
    Vaccine; 2009 Feb 05; 27(6):947-55. PubMed ID: 19059296
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB.
    Clin Infect Dis; 2006 Nov 01; 43(9):1135-42. PubMed ID: 17029131
    [Abstract] [Full Text] [Related]

  • 4. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.
    Sci Transl Med; 2010 Jan 20; 2(15):15ra5. PubMed ID: 20371470
    [Abstract] [Full Text] [Related]

  • 5. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A.
    Vaccine; 2008 May 02; 26(19):2350-9. PubMed ID: 18400340
    [Abstract] [Full Text] [Related]

  • 6. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B.
    Vaccine; 2007 Dec 21; 26(1):119-27. PubMed ID: 18063446
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
    Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, Smith G, Wright DC, Bright RA.
    Vaccine; 2007 May 22; 25(21):4283-90. PubMed ID: 17403562
    [Abstract] [Full Text] [Related]

  • 8. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.
    Madhun AS, Haaheim LR, Nilsen MV, Cox RJ.
    Vaccine; 2009 Dec 09; 27(52):7367-76. PubMed ID: 19781678
    [Abstract] [Full Text] [Related]

  • 9. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J, Wang F, Fang F, Zhang W, Chang H, Zheng L, Chen Z.
    Arch Virol; 2011 Mar 09; 156(3):387-95. PubMed ID: 21110049
    [Abstract] [Full Text] [Related]

  • 10. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.
    Pediatr Infect Dis J; 2009 Jul 09; 28(7):563-71. PubMed ID: 19561422
    [Abstract] [Full Text] [Related]

  • 11. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S, Tagliaferri L, Daleno C, Valzano A, Picciolli I, Tel F, Prunotto G, Serra D, Galeone C, Plebani A, Principi N.
    Vaccine; 2011 Feb 11; 29(8):1677-82. PubMed ID: 21199699
    [Abstract] [Full Text] [Related]

  • 12. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
    Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P.
    Vaccine; 2008 Mar 17; 26(12):1525-9. PubMed ID: 18294741
    [Abstract] [Full Text] [Related]

  • 13. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C, Piras F, Bernard MC, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste C, Kusters I.
    Vaccine; 2010 Apr 19; 28(18):3076-9. PubMed ID: 20193791
    [Abstract] [Full Text] [Related]

  • 14. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF.
    Vaccine; 2010 Jan 08; 28(3):840-8. PubMed ID: 19835829
    [Abstract] [Full Text] [Related]

  • 15. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 16. Systemic immune responses to an inactivated, whole H9N2 avian influenza virus vaccine using class B CpG oligonucleotides in chickens.
    Singh SM, Alkie TN, Hodgins DC, Nagy É, Shojadoost B, Sharif S.
    Vaccine; 2015 Jul 31; 33(32):3947-52. PubMed ID: 26092309
    [Abstract] [Full Text] [Related]

  • 17. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.
    Vaccine; 2010 Jan 08; 28(3):849-57. PubMed ID: 19835828
    [Abstract] [Full Text] [Related]

  • 18. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.
    Hehme N, Engelmann H, Künzel W, Neumeier E, Sänger R.
    Med Microbiol Immunol; 2002 Dec 08; 191(3-4):203-8. PubMed ID: 12458361
    [Abstract] [Full Text] [Related]

  • 19. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M.
    Vaccine; 2009 Oct 23; 27(45):6291-5. PubMed ID: 19840662
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.
    Nicholson KG, Thompson CI, Klap JM, Wood JM, Batham S, Newman RW, Mischler R, Zambon MC, Stephenson I.
    Vaccine; 2009 Dec 10; 28(1):171-8. PubMed ID: 19799843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.